Overview
- Every analyst polled by CNN Business now has a buy rating on Teva and their 12‑month targets imply about 28% to 60% upside from current prices.
- Teva has shifted under CEO Richard Francis from a generics focus to branded drugs, with Austedo growing 41% to $559 million and management raising full‑year Austedo guidance to $2.4 billion–$2.55 billion.
- Sales from generics and biosimilars are shrinking, with Q1 generics revenue reported at $612 million, down 28% year‑over‑year, making branded launches central to near‑term growth.
- The company still faces clear risks including costly drug development, pipeline uncertainty and a decade of share underperformance that leaves gains dependent on future product success.
- Investors should watch Teva's pipeline catalysts such as the co‑developed duvakitug trials and upcoming biosimilars because positive clinical news could materially boost revenue while failures would set back the turnaround.